CCM
TCRT icon

Cadence Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Cadence Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-96
Closed -$61K – 455
2019
Q3 		$61K Buy
+96
New +$76.2K 0.01% 413

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cadence Capital Management's TCRT Position: Q4 2019 in Review

Cadence Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 96 shares — an estimated $61K sold.

Cadence Capital Management first reported a position in TCRT in Q3 2019 and held it in 1 quarter. The position peaked at $61K in Q3 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • Cadence Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Cadence Capital Management sold 96 Alaunos Therapeutics shares in Q4 2019, an estimated $61K.
  • Cadence Capital Management first reported a position in Alaunos Therapeutics in Q3 2019 and held it in 1 quarter.
  • Cadence Capital Management's Alaunos Therapeutics position peaked at $61K in Q3 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on Cadence Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.